{"id":"NCT04410978","sponsor":"Sanofi","briefTitle":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","officialTitle":"A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-30","primaryCompletion":"2024-07-15","completion":"2024-07-15","firstPosted":"2020-06-01","resultsPosted":"2025-06-18","lastUpdate":"2025-07-02"},"enrollment":974,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Tolebrutinib","otherNames":["SAR442168"]},{"type":"DRUG","name":"Teriflunomide","otherNames":[]},{"type":"DRUG","name":"Placebo to match Tolebrutinib","otherNames":[]},{"type":"DRUG","name":"Placebo to match Teriflunomide","otherNames":[]}],"arms":[{"label":"SAR442168","type":"EXPERIMENTAL"},{"label":"Teriflunomide","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS\n\nSecondary Objective:\n\nTo assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168","primaryOutcome":{"measure":"Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated Relapses","timeFrame":"Baseline (Day 1) to approximately 48 months","effectByArm":[{"arm":"Teriflunomide 14 mg","deltaMin":0.122,"sd":null},{"arm":"Tolebrutinib 60 mg","deltaMin":0.13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6691"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":12},"locations":{"siteCount":179,"countries":["United States","Austria","Belarus","Bulgaria","Canada","China","Czechia","Denmark","Estonia","Finland","Germany","Hong Kong","Italy","Japan","Lithuania","Mexico","Poland","Romania","Russia","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["40202623"],"seeAlso":["https://sanofi.trialsummaries.com/Study/StudyDetails?id=25237&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":488},"commonTop":["Covid-19","Alopecia","Nasopharyngitis","Headache","Upper Respiratory Tract Infection"]}}